{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:51:42Z","timestamp":1790607102372,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA-DA000635"],"award-info":[{"award-number":["ZIA-DA000635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N95023P00806"],"award-info":[{"award-number":["75N95023P00806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry Global Open Science"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bpsgos.2025.100659","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:43:56Z","timestamp":1763970236000},"page":"100659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use: A Real-Word Observational Study in a Large, Integrated Health Care System"],"prefix":"10.1016","volume":"6","author":[{"given":"Vanessa A.","family":"Palzes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Costales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kline-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-8754","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpsgos.2025.100659_bib2","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 receptor agonists: Promising therapeutic targets for alcohol use disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpsgos.2025.100659_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70004","article-title":"Effects of GLP-1 receptor agonists in alcohol use disorder","volume":"136","author":"Klausen","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bpsgos.2025.100659_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies","volume":"14","author":"Jerlhag","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBiomedicine"},{"key":"10.1016\/j.bpsgos.2025.100659_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2025.100659_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bpsgos.2025.100659_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","volume":"242","author":"Fink-Jensen","year":"2025","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.bpsgos.2025.100659_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.bpsgos.2025.100659_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.bpsgos.2025.100659_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/science.adt0773","article-title":"Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety","volume":"387","author":"Zhu","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.bpsgos.2025.100659_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105684","article-title":"An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents","volume":"115","author":"Edvardsson","year":"2025","journal-title":"EBiomedicine"},{"key":"10.1016\/j.bpsgos.2025.100659_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.physbeh.2013.04.003","article-title":"Role of central glucagon-like peptide-1 in stress regulation","volume":"122","author":"Ghosal","year":"2013","journal-title":"Physiol Behav"},{"key":"10.1016\/j.bpsgos.2025.100659_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110303","article-title":"The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: A review","volume":"110","author":"Guerrero-Hreins","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Mental Health"},{"key":"10.1016\/j.bpsgos.2025.100659_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bpsgos.2025.100659_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: Evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13211","article-title":"The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Addict Biol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17190-3","article-title":"Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use","volume":"12","author":"Farokhnia","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpsgos.2025.100659_bib21","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bpsgos.2025.100659_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2025.100659_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib25","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsgos.2025.100659_bib26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.bpsgos.2025.100659_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.bpsgos.2025.100659_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpsgos.2025.100659_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7812\/TPP\/22.172","article-title":"Comparing Kaiser Permanente members to the general population: Implications for generalizability of research","volume":"27","author":"Davis","year":"2023","journal-title":"Permanente J"},{"key":"10.1016\/j.bpsgos.2025.100659_bib31","series-title":"Pharmacoepidemiology","first-page":"241","article-title":"Kaiser Permanente medical care program","author":"Selby","year":"2005"},{"key":"10.1016\/j.bpsgos.2025.100659_bib32","article-title":"Contextual factors associated with successful alcohol screening and brief intervention implementation and sustainment in adult primary care","volume":"168","author":"Sterling","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.bpsgos.2025.100659_bib33","article-title":"How to apply the NIAAA core resource on alcohol in clinical practice","year":"2023","journal-title":"Healthcare Professional\u2019s Core Resource on Alcohol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.bpsgos.2025.100659_bib35","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s11524-006-9094-x","article-title":"The development of a standardized neighborhood deprivation index","volume":"83","author":"Messer","year":"2006","journal-title":"J Urban Health"},{"key":"10.1016\/j.bpsgos.2025.100659_bib36","article-title":"Adult BMI categories","year":"2024","journal-title":"BMI"},{"key":"10.1016\/j.bpsgos.2025.100659_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11920-019-1070-8","article-title":"Changes in alcohol use after metabolic and bariatric surgery: Predictors and mechanisms","volume":"21","author":"Ivezaj","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.bpsgos.2025.100659_bib38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.bpsgos.2025.100659_bib40","series-title":"Alcohol and Alcohol-Related Diseases","first-page":"261","article-title":"Approved, promising, and experimental medications for treatment of alcohol use disorder","author":"L\u00e9k\u00f3","year":"2023"},{"key":"10.1016\/j.bpsgos.2025.100659_bib41","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/s41386-021-01117-z","article-title":"Effectiveness of spironolactone dispensation in reducing weekly alcohol use: A retrospective high-dimensional propensity score-matched cohort study","volume":"46","author":"Palzes","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpsgos.2025.100659_bib42","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1038\/s41380-022-01736-y","article-title":"Spironolactone as a potential new pharmacotherapy for alcohol use disorder: Convergent evidence from rodent and human studies","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.bpsgos.2025.100659_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.bpsgos.2025.100659_bib45","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/aje\/kwy049","article-title":"Relative performance of propensity score matching strategies for subgroup analyses","volume":"187","author":"Wang","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib46","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.bpsgos.2025.100659_bib47","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.bpsgos.2025.100659_bib48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ndt\/gfx198","article-title":"Cautionary note: Propensity score matching does not account for bias due to censoring","volume":"33","author":"Penning de Vries","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bpsgos.2025.100659_bib49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","article-title":"Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: A secondary analysis of 3 randomized clinical trials","volume":"76","author":"Falk","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib50","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1530-0277.2010.01290.x","article-title":"Percentage of subjects with no heavy drinking days: Evaluation as an efficacy endpoint for alcohol clinical trials","volume":"34","author":"Falk","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.bpsgos.2025.100659_bib51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/0962280210395740","article-title":"Review of inverse probability weighting for dealing with missing data","volume":"22","author":"Seaman","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.bpsgos.2025.100659_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109458","article-title":"Alcohol brief intervention, specialty treatment and drinking outcomes at 12 months: Results from a systematic alcohol screening and brief intervention initiative in adult primary care","volume":"235","author":"Chi","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.bpsgos.2025.100659_bib53","first-page":"344","article-title":"The association between health changes and cessation of alcohol consumption","volume":"52","author":"Park","year":"2017","journal-title":"Alcohol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/ADM.0000000000000767","article-title":"Alcohol consumption in response to the COVID-19 pandemic in the United States","volume":"15","author":"Barbosa","year":"2021","journal-title":"J Addict Med"},{"key":"10.1016\/j.bpsgos.2025.100659_bib55","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.bpsgos.2025.100659_bib56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s40429-018-0208-9","article-title":"Overeating, overweight, and substance use: What is the connection?","volume":"5","author":"Saules","year":"2018","journal-title":"Curr Addict Rep"},{"key":"10.1016\/j.bpsgos.2025.100659_bib57","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/s41380-025-03259-8","article-title":"Crosstalk between alcohol use disorder and obesity: Two sides of the same coin?","volume":"30","author":"Leggio","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2025.100659_bib58","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae165","article-title":"GLP-1 and its analogs: Does sex matter?","volume":"166","author":"B\u00f6rchers","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpsgos.2025.100659_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13293-022-00441-3","article-title":"Consideration of sex and gender differences in addiction medication response","volume":"13","author":"McKee","year":"2022","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.bpsgos.2025.100659_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/molecules22010022","article-title":"Rate of homologous desensitization and internalization of the GLP-1 receptor","volume":"22","author":"Shaaban","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bpsgos.2025.100659_bib61","first-page":"62","article-title":"Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate","volume":"10","author":"Widmann","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib62","doi-asserted-by":"crossref","first-page":"19957","DOI":"10.1074\/jbc.271.33.19957","article-title":"Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites","volume":"271","author":"Widmann","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpsgos.2025.100659_bib63","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"issue":"suppl 3","key":"10.1016\/j.bpsgos.2025.100659_bib64","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.2337\/diabetes.53.suppl_3.S205","article-title":"Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bpsgos.2025.100659_bib65","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/db13-0893","article-title":"Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia","volume":"63","author":"Umapathysivam","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.bpsgos.2025.100659_bib66","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1210\/jc.2017-00199","article-title":"Tolerance does not develop toward liraglutide\u2019s glucose-lowering effect","volume":"102","author":"Sedman","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpsgos.2025.100659_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173443","article-title":"Tolerance develops toward GLP-1 receptor agonists\u2019 glucose-lowering effect in mice","volume":"885","author":"Sedman","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib68","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.bpsgos.2025.100659_bib69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bja.2024.04.049","article-title":"GLP-1 receptor agonist tachyphylaxis and perioperative recommendations","volume":"133","author":"Wu","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpsgos.2025.100659_bib70","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bpsgos.2025.100659_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13441","article-title":"The glucagon-like peptide-1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery","volume":"29","author":"Molina-Castro","year":"2024","journal-title":"Addict Biol"},{"key":"10.1016\/j.bpsgos.2025.100659_bib72","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/aje\/kwae019","article-title":"Quasi-experimental methods for pharmacoepidemiology: Difference-in-differences and synthetic control methods with case studies for vaccine evaluation","volume":"193","author":"Kennedy-Shaffer","year":"2024","journal-title":"Am J Epidemiol"}],"container-title":["Biological Psychiatry Global Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174325002137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174325002137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:45:37Z","timestamp":1780101937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667174325002137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2667174325002137"],"URL":"https:\/\/doi.org\/10.1016\/j.bpsgos.2025.100659","relation":{},"ISSN":["2667-1743"],"issn-type":[{"value":"2667-1743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use: A Real-Word Observational Study in a Large, Integrated Health Care System","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry Global Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsgos.2025.100659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}],"article-number":"100659"}}